~~<i id='4955002206'><strike id='4955002206'><tt id='4955002206'><pre id='4955002206'></pre></tt></strike></i>~~

Home» knowledge» leisure time

leisure time

author：fashion 2025-10-04 09:14:43 Page View：918

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hospitals are dialing back on venture capital investing
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

explore

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

FDA's Woodcock to retire early next year

PrincipalDeputyFDACommissionerJanetWoodcockStefaniReynolds/TheNewYorkTimesviaAPWASHINGTON—PrincipalD

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Patients, digital health players weigh in on FTC's data privacy plan

AdobeThisyearhasseentheFederalTradeCommissioncrackdownondigitalhealthcompanies’irresponsibledatause.